Corteva Agriscience

CEO Chuck Magro, who joined from Nutrien in November 2023, sets the capital allocation framework alongside CFO Dave Anderson. The board of directors, chaired by former Bunge CEO Soren Schroder, approves major M&A and share buyback programs. Day-to-day corporate development and venture investments are executed by the corporate strategy team reporting through the CFO.

Corteva runs a direct corporate venture and collaboration model rather than a standalone venture fund. It partners with ag-biotech startups through its Delta platform, makes selective acquisitions like Stoller Group ($1.2B, 2023) for biologicals, and executes licensing agreements for gene-editing tools such as CRISPR Cas-12 from MIT's Broad Institute. This hybrid approach keeps novel trait discovery external while commercialization stays in-house.

Corteva is a pure-play agricultural company with no pharmaceuticals, consumer health, or materials division. Bayer Crop Science, by contrast, operates inside a conglomerate that also sells prescription drugs and over-the-counter products. This means Corteva's regulatory risk, patent expiration calendar, and capital allocation are fully transparent and dedicated to agriculture alone, with no internal capital competition from higher-margin pharma units.